Matot I, Pizov R, Sprung C L
Department of Anesthesiology and Critical Care Medicine, Institute of Medicine, Ethics and Law, Hadassah University Medical Center, Hebrew University of Jerusalem, Israel.
Crit Care Med. 1998 Sep;26(9):1596-602. doi: 10.1097/00003246-199809000-00035.
To examine the frequency of obtaining Institutional Review Board (IRB) approval and informed consent in critical care research.
One-year retrospective review of original critical care research in humans published in seven journals, including American Journal of Respiratory and Critical Care Medicine, Chest, Critical Care Medicine, Intensive Care Medicine, The Journal of the American Medical Association, Lancet, and The New England Journal of Medicine. Studies were examined for general information (country/state where the research was performed, affiliation of the hospital to a medical school, and whether the work was supported by a grant and specifically by a pharmaceutical company), approval by IRB, method of consent, design of research, and interventions involved in the study.
Two hundred seventy-nine studies were reviewed, 124 (44%) of which were conducted in the United States. Two hundred forty-three (87%) studies were performed in a university institution, 96 (34%) studies were supported by a grant, and 23 (24%) studies were supported by a pharmaceutical company. In 66 (24%) studies, there was no evidence of IRB review and informed consent approval. IRB approval was obtained but the method of consent was not specified in 36 (13%) studies. No significant differences were found in obtaining IRB approval and informed consent between research conducted in the United States (n=71, 57%) or outside the United States (n=92, 59%). Grant support was obtained in ten (9%) of the 116 studies not fully approved, compared with 70 (50%) of the 140 studies that obtained full approval (p < .05). All studies (23) supported by the pharmaceutical industry were fully approved.
Many published studies in critical care lack IRB approval and/or informed consent. All research supported by the pharmaceutical industry was fully approved. The findings raise ethical concerns about critical care research.
研究重症监护研究中获得机构审查委员会(IRB)批准和知情同意的频率。
对发表在七种期刊上的关于人类重症监护原始研究进行为期一年的回顾,这些期刊包括《美国呼吸与重症医学杂志》《胸部》《重症医学》《重症监护医学》《美国医学会杂志》《柳叶刀》和《新英格兰医学杂志》。对研究进行如下审查:一般信息(研究开展的国家/州、医院与医学院的附属关系、研究是否获得资助,特别是是否由制药公司资助)、IRB批准情况、同意方式、研究设计以及研究涉及的干预措施。
共审查了279项研究,其中124项(44%)在美国开展。243项(87%)研究在大学机构进行,96项(34%)研究获得资助,23项(24%)研究由制药公司资助。66项(24%)研究没有IRB审查和知情同意批准的证据。36项(13%)研究获得了IRB批准,但未说明同意方式。在美国开展的研究(n = 71,57%)和美国以外开展的研究(n = 92,59%)在获得IRB批准和知情同意方面未发现显著差异。在116项未完全批准的研究中,有10项(9%)获得了资助,而在140项获得完全批准的研究中,有70项(50%)获得了资助(p < 0.05)。所有由制药行业资助的研究(23项)均获得完全批准。
许多已发表的重症监护研究缺乏IRB批准和/或知情同意。所有由制药行业资助的研究均获得完全批准。这些发现引发了对重症监护研究的伦理关注。